Causes of death in locally advanced esophageal cancer undergoing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy: a retrospective cohort study.

IF 2.6 3区医学

Diseases of the Esophagus Pub Date : 2025-03-03 DOI:10.1093/dote/doaf017

Dong Liu, Huan-Wei Liang, Yang Liu, Wei Huang, Xin-Bin Pan

{"title":"Causes of death in locally advanced esophageal cancer undergoing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy: a retrospective cohort study.","authors":"Dong Liu, Huan-Wei Liang, Yang Liu, Wei Huang, Xin-Bin Pan","doi":"10.1093/dote/doaf017","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the causes of death in patients with locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed by surgery.Materials and methods: A retrospective cohort study was conducted on patients with stage T3-4aN0M0/T1-4aN1-3 M0 esophageal cancer who underwent either neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy followed by surgery. Overall survival (OS) and specific causes of death were analyzed and compared between the two treatment groups.Results: A total of 4528 patients were included: 333 (7.4%) received neoadjuvant chemotherapy, and 4195 (92.6%) underwent neoadjuvant chemoradiotherapy. The 5-year OS was comparable between the two groups, both before (42.4% vs. 39.7%; hazard ratio [HR] = 1.14, 95% confidence interval [CI]: 0.98-1.33; P = 0.097) and after (42.2% vs. 42.2%; HR = 1.07, 95% CI: 0.86-1.31; P = 0.567) propensity score matching. The cumulative 5-year absolute risk of death from esophageal cancer (49.9% vs. 50.6%, P = 0.470), death from non-tumor causes (7.8% vs. 9.7%, P = 0.160), death due to lung causes (2.8% vs. 1.4%, P = 0.432), and death from heart-related causes (2.2% vs. 2.0%, P = 0.524) were similar between the two treatment groups.Conclusion: In patients with locally advanced esophageal cancer, OS and the causes of death were comparable between those receiving neoadjuvant chemotherapy and those undergoing neoadjuvant chemoradiotherapy.","PeriodicalId":54277,"journal":{"name":"Diseases of the Esophagus","volume":"38 2","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases of the Esophagus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/dote/doaf017","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare the causes of death in patients with locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed by surgery.

Materials and methods: A retrospective cohort study was conducted on patients with stage T3-4aN0M0/T1-4aN1-3 M0 esophageal cancer who underwent either neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy followed by surgery. Overall survival (OS) and specific causes of death were analyzed and compared between the two treatment groups.

Results: A total of 4528 patients were included: 333 (7.4%) received neoadjuvant chemotherapy, and 4195 (92.6%) underwent neoadjuvant chemoradiotherapy. The 5-year OS was comparable between the two groups, both before (42.4% vs. 39.7%; hazard ratio [HR] = 1.14, 95% confidence interval [CI]: 0.98-1.33; P = 0.097) and after (42.2% vs. 42.2%; HR = 1.07, 95% CI: 0.86-1.31; P = 0.567) propensity score matching. The cumulative 5-year absolute risk of death from esophageal cancer (49.9% vs. 50.6%, P = 0.470), death from non-tumor causes (7.8% vs. 9.7%, P = 0.160), death due to lung causes (2.8% vs. 1.4%, P = 0.432), and death from heart-related causes (2.2% vs. 2.0%, P = 0.524) were similar between the two treatment groups.

Conclusion: In patients with locally advanced esophageal cancer, OS and the causes of death were comparable between those receiving neoadjuvant chemotherapy and those undergoing neoadjuvant chemoradiotherapy.

查看原文本刊更多论文

局部晚期食管癌接受新辅助化疗和新辅助放化疗的死亡原因：一项回顾性队列研究。

目的：比较局部晚期食管癌患者接受新辅助化疗与新辅助放化疗后手术的死亡原因。材料与方法：对T3-4aN0M0/T1-4aN1-3 M0期食管癌患者进行新辅助化疗或新辅助放化疗后手术的回顾性队列研究。分析比较两组患者的总生存期（OS）和具体死亡原因。结果：共纳入4528例患者，其中333例（7.4%）接受新辅助化疗，4195例（92.6%）接受新辅助放化疗。两组的5年OS具有可比性，均为术前(42.4% vs. 39.7%；风险比[HR] = 1.14, 95%可信区间[CI]: 0.98-1.33；P = 0.097)和术后(42.2% vs. 42.2%；Hr = 1.07, 95% ci: 0.86-1.31；P = 0.567)倾向得分匹配。食管癌死亡的累积5年绝对风险（49.9%比50.6%,P = 0.470）、非肿瘤原因死亡（7.8%比9.7%,P = 0.160）、肺原因死亡（2.8%比1.4%,P = 0.432）和心脏相关原因死亡（2.2%比2.0%,P = 0.524）在两个治疗组之间相似。结论：在局部晚期食管癌患者中，接受新辅助化疗和接受新辅助放化疗的OS和死亡原因相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diseases of the Esophagus Medicine-Gastroenterology

自引率

7.70%

发文量

568

期刊介绍： Diseases of the Esophagus covers all aspects of the esophagus - etiology, investigation and diagnosis, and both medical and surgical treatment.